Shiga Toxin-Producing Escherichia coli Infection and Antibodies against Stx2 and Stx1 in Household Contacts of Children with Enteropathic Hemolytic-Uremic Syndrome

ABSTRACT Ninety-five household contacts (aged 2 months to 73 years) of patients with enteropathic hemolytic-uremic syndrome (HUS) were investigated for the presence of immunoglobulin (Ig) G antibodies to Shiga toxins Stx2 and Stx1 by Western blot assay. Thirty-one percent of the household contacts and 19% of 327 controls had anti-Stx2 IgG (heavy and light chain [H + L]), 5 and 8%, respectively, had anti-Stx1 IgG (H + L), and 3 and 2%, respectively, had both anti-Stx2 and anti-Stx1 IgG (H + L). The incidence of infections with Stx-producing Escherichia coli (STEC) was determined based on the following diagnostic criteria: STEC isolation, detection of stx gene sequences, free fecal Stx in stool filtrates, and serum IgM antibodies against E. coli O157 lipopolysaccharide. Evidence of STEC infection was observed in 25 household contacts, of whom 18 (72%) were asymptomatic and represented a potential source of infection. Six of 13 (46%) household contacts with Stx2-producing E. coli O157:H7 in stool culture developed anti-Stx2 IgG (H + L), compared to 71% of Stx2-associated HUS cases. In individuals showing anti-Stx2 IgG (H + L), the antibody response was directed against the B subunit in 69% of household contacts and 71% of controls, in contrast to 28% of HUS patients. In this investigation controls had a significant increase of the median of IgM antibodies to O157 lipopolysaccharide (LPS) with age, up to the fifth decade. The lack of disease in household contacts with B subunit-specific antibodies, as well as the significantly higher median of anti-O157 LPS IgM antibodies in controls beyond 4.9 years of age, suggests a protective role for anti-Stx and anti-O157 LPS antibodies.

[1]  D. Malkin,et al.  A family outbreak of hemolytic-uremic syndrome associated with verotoxin-producingEscherichia coli serotype 0157:H7 , 1988, Pediatric Nephrology.

[2]  H. Lior,et al.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. 1985. , 1985, The Journal of infectious diseases.

[3]  H. Karch,et al.  Antibody Response to Shiga Toxins Stx2 and Stx1 in Children with Enteropathic Hemolytic-Uremic Syndrome , 2001, Journal of Clinical Microbiology.

[4]  I. Poxton,et al.  Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. , 2001, Journal of medical microbiology.

[5]  E. López,et al.  Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America. , 2000, Infectious disease clinics of North America.

[6]  H. Karch,et al.  Molecular characteristics and epidemiological significance of Shiga toxin-producing Escherichia coli O26 strains. , 2000, Journal of clinical microbiology.

[7]  L. Monnens,et al.  Verocytotoxin-producing Escherichia coli infection in household members of children with hemolytic-uremic syndrome in The Netherlands. , 1999, The Pediatric infectious disease journal.

[8]  H. Karch,et al.  Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. , 1999, Diagnostic microbiology and infectious disease.

[9]  Y. Mizumoto,et al.  Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996 , 1999, Pediatrics international : official journal of the Japan Pediatric Society.

[10]  T. D. de Koning-Ward,et al.  Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  H. Karch,et al.  Shiga Toxin-Producing Escherichia coli Infections in Germany †. , 1997, Journal of food protection.

[12]  M. Petric,et al.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits , 1997, Infection and immunity.

[13]  M. Winkler,et al.  Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1 , 1997, Journal of clinical microbiology.

[14]  M. Bitzan,et al.  Immune response to non-O157 Vero toxin-producing Escherichia coli in patients with hemolytic uremic syndrome. , 1996, The Journal of infectious diseases.

[15]  M. Winkler,et al.  Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents , 1996, Journal of clinical microbiology.

[16]  H. Karch,et al.  Isolation of enterohemorrhagic Escherichia coli O157 strains from patients with hemolytic-uremic syndrome by using immunomagnetic separation, DNA-based methods, and direct culture , 1996, Journal of clinical microbiology.

[17]  M. Rivas,et al.  Verocytotoxin-producing Escherichia coli infection in family members of children with hemolytic uremic syndrome. , 1996, Medicina.

[18]  H. Karch,et al.  Long-term shedding and clonal turnover of enterohemorrhagic Escherichia coli O157 in diarrheal diseases , 1995, Journal of clinical microbiology.

[19]  K. Sandvig,et al.  Furin-induced Cleavage and Activation of Shiga Toxin (*) , 1995, The Journal of Biological Chemistry.

[20]  H. Karch,et al.  An outbreak due to enterohaemorrhagic Escherichia coli O157:H7 in a children day care centre characterized by person-to-person transmission and environmental contamination. , 1994, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[21]  H. Karch,et al.  Prevalence of attaching and effacing Escherichia coli in stool samples from patients and controls. , 1994, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[22]  G. Nair,et al.  Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1 , 1994, Journal of clinical microbiology.

[23]  J. Heesemann,et al.  Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. , 1994, Journal of medical microbiology.

[24]  G. Thorne,et al.  Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects , 1994, Journal of clinical microbiology.

[25]  H. Lior,et al.  Epidemic Escherichia coli O157: H7 gastroenteritis and hemolytic-uremic syndrome in a Canadian Inuit community: Intestinal illness in family members as a risk factor , 1994 .

[26]  A. Edefonti,et al.  Communitywide Outbreak of Hemolytic-Uremic Syndrome Associated with Non-O157 Verocytotoxin-Producing Escherichia coli , 1994 .

[27]  A. Edefonti,et al.  Community-wide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli. , 1994, The Journal of infectious diseases.

[28]  A. Leung,et al.  Recurrent hemorrhagic colitis caused by Escherichia coli O157:H7. , 1993, The Pediatric infectious disease journal.

[29]  H. König,et al.  The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: Results of a Central European, multicentre study , 1993, Epidemiology and Infection.

[30]  T. Barrett,et al.  Recurrent hemolytic uremic syndrome secondary to Escherichia coli O157:H7 infection. , 1993, Pediatrics.

[31]  M. Osterholm,et al.  Transmission of Escherichia coli O157:H7 infection in Minnesota child day-care facilities. , 1993, JAMA.

[32]  V. Jay,et al.  Experimental verocytotoxemia in rabbits , 1992, Infection and immunity.

[33]  H. Karch,et al.  DNA fingerprinting of Escherichia coli O157:H7 strains by pulsed-field gel electrophoresis , 1992, Journal of clinical microbiology.

[34]  F. Gunzer,et al.  Molecular detection of sorbitol-fermenting Escherichia coli O157 in patients with hemolytic-uremic syndrome , 1992, Journal of clinical microbiology.

[35]  M. P. Jackson,et al.  Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. , 1992, Current topics in microbiology and immunology.

[36]  H. Karch,et al.  A biotyping scheme for Shiga-like (Vero) toxin-producing Escherichia coli O157 and a list of serological cross-reactions between O157 and other gram-negative bacteria. , 1992, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[37]  H. Karch,et al.  High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. , 1991, The Journal of pediatrics.

[38]  E. Orrbine,et al.  Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre. , 1991, The Journal of pediatrics.

[39]  D. Milford,et al.  Literature abstracts , 1991, The Lancet.

[40]  B. Murray,et al.  Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome. , 1991, The Pediatric infectious disease journal.

[41]  R. Tauxe,et al.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. , 1991, Epidemiologic reviews.

[42]  P. Tarr,et al.  Escherichia coli 0157:H7 and the Hemolytic Uremic Syndrome: Importance of Early Cultures in Establishing the Etiology , 1990 .

[43]  J. Wells,et al.  Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. , 1990, The Journal of pediatrics.

[44]  M. Karmali,et al.  Infection by verocytotoxin-producing Escherichia coli , 1989, Clinical Microbiology Reviews.

[45]  M. Petric,et al.  Purification and characterization of verocytotoxin 2 , 1988 .

[46]  C. Pai,et al.  Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study. , 1988, The Journal of infectious diseases.

[47]  J. Carlson,et al.  A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. , 1987, The New England journal of medicine.

[48]  M. Petric,et al.  Purification and biological properties of Escherichia coli verocytotoxin , 1987 .

[49]  J. Wells,et al.  Hemolytic uremic syndrome and diarrhea associated with Escherichia coli 0157:H7 in a day care center , 1986 .

[50]  R. Holmes,et al.  Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities , 1986, Infection and immunity.

[51]  J. Friesen,et al.  Cloning and expression of the genes specifying Shiga-like toxin production in Escherichia coli H19 , 1986, Journal of bacteriology.

[52]  J. Wells,et al.  Hemolytic uremic syndrome and diarrhea associated with Escherichia coli O157:H7 in a day care center. , 1986, The Journal of pediatrics.

[53]  J. Wells,et al.  Hemorrhagic colitis associated with a rare Escherichia coli serotype. , 1983, The New England journal of medicine.

[54]  M. Petric,et al.  SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS , 1983, The Lancet.

[55]  J. S. Fong,et al.  Hemolytic-Uremic Syndrome: Current Concepts and Management , 1982 .

[56]  C. Merril,et al.  Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. , 1981, Science.

[57]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.